The concept of aesthetic treatments using radiofrequency is not new and has been in the industry for well over a decade. However, the level of innovation has significantly increased during recent years. Prominently, the number of regulatory approvals and new offerings has increased during the pandemic. The global radiofrequency-based aesthetic devices market features a highly complex and competitive technological landscape. Technology is one of the primary differentiators in this field. Consequently, companies put a strong emphasis on the development of intellectual property (IP). Companies operating in the market have a vast array of products lined up, each of them compatible with their proprietary technology.

Heparin is an anticoagulant medication and a naturally occurring glycosaminoglycan produced by basophils and mast cells in all mammals. Heparin is used to prevent formation of blood clots caused by certain medical conditions or medical procedures. The report provides market dynamics and trends related to the global heparin market. The study estimates the revenue generated from the sales of heparin products; however, it excludes the heparin products service revenue. The valuations comprise revenue generated from heparin products such as unfractionated heparin, low molecular weight heparin, and ultra-low molecular weight heparin.

Currently, the field of radiation therapy is changing in terms of radiation type, and there are several changes in adoption patterns among its end-user segments. The end users are shifting from conventional radiation (Xray, or Cobalt-60, among others) to modern radiation such as a proton or heavy ion radiation. The increasing demand for modern radiation therapy systems has led to the increasing awareness of cancer/tumor treatments. The primary role of these systems is to shrink or destroy cancer/tumor depending on cancer/tumor type, stage, patient age, number of radiation sessions required, and many other factors. Radiation therapy can be divided primarily into external beam radiation therapy, also known as teletherapy, and internal beam radiation therapy, also known as brachytherapy. In the past decade, the definition of these technologies has expanded. Earlier the radiation therapy was only referred to as a simple therapy only done by the radiation beam. Now, radiation therapy includes internal radiation or external radiation combined with chemotherapy or open body surgery or combining various radiation therapy techniques such as IGRT, VMAT, and SRS to destroy or shrink cancer/ tumor. The ongoing trend of offering new radiation therapy systems which have proton or heavy ion beam, integration of two different radiation therapies, and integration of imaging technology with radiation therapy systems showcase the growing future of technological innovations and advancements in radiation therapy in the oncology field.

Direct-to-consumer genetic tests (DTC-GT) offers its consumers the ability to solve their individual genetic puzzle. The confluence of breakthroughs in genetic testing has not only decreased the time required to perform a genetic test but also has reduced the cost of conducting these tests. All these factors combined have given DTC-GT a lot of acceptance among the consumers. The major proponent of the DTC-GT market is the distribution channels opted by the companies. The companies are marketing these tests via online or retail channels. With the piqued advertisements of these tests through print, media, and the internet, the industry is gaining familiarity among consumers. Companies such as 23andme, Mapmygenome, Ancestry.com, EasyDNA, and 24Genetic are offering a large number of diversified services related to genealogy testing, health conditions, and traits. The journey of the DTC-GT initiates by a consumer ordering the test through an online channel. The sample collection kit is provided to the consumers. DNA sample such as saliva or oral swab is collected by the consumer and sent back to the organization for the analysis. Consumers get their test results on their online account within 3-5 weeks.

The Food and Drug Administration (FDA) regulates medical devices in the U.S. to ensure their effectiveness and safety for patients and users. The FDA's Center for Devices and Radiological Health (CDRH) oversees regulating these firms. The FDA must approve every company involved in the manufacturing, packaging, labeling, and/or sale of medical devices sold in the U.S. Electrocardiographs are classified into Class II categories of medical devices in the U.S. These systems are considered as medical devices through the Federal Food, Drug and Cosmetic (FD&C) Act. Diagnostic imaging systems are classified under the category of non-501(k)-exempt Class I and Class II medical devices and do not follow the Pre-Marketing Approval (PMA) pathway by U.S. Food and Drug Administration (FDA). In 501(k) pathways, any new diagnostic imaging devices under Class I and Class II should be legally marketed and should have a clear definition of technological characteristics, applications, and indications.

The global surgical instrument tracking devices market is expected to grow at a CAGR of 9.16% for the forecast period 2021-2031. Leading market players strive to retain a competitive edge by having a good presence in key markets and offering a diverse product range. The market has witnessed a total of 32 key developments over the five years (January 2016-March 2021), with a majority of them being product offerings and upgradation accompanied by partnerships, alliances, and business expansions. Efforts are being made to bring more technologically innovative goods to market, each aimed at a particular unmet need. With the launch of new and updated devices with improved features, surgical instrument tracking devices technology has become increasingly possible to unlock new use cases.

Health insurance covers medical expenses incurred during treatment of any disease, injury, or other mental & physical impairment. It acts as compensation in exchange for a monthly/semi-annual/annual premium or a payroll tax to provide healthcare benefits. The insurer is obliged to cover medical expenses for the policy holder up till the tenure and coverage of the policy. Depending on the policy, the coverage may vary for numerous factors, including diseases, age group, government policies, and others.

Practically overnight, clinicians, healthcare providers, pharmaceutical companies and payers shifted much of their work onto virtual platforms and other digital technologies. As consumers grappled with a deadly new virus, providers embraced virtual technology in unprecedented numbers so they could continue to serve patients despite restrictions on in-person interactions. In doing so, they packed a decade’s worth of reforms into a few short months. Players across the industry boosted data analytics capabilities to respond to ongoing shifts in healthcare needs, consumer behaviour and the economy. The deployment of digital tools in clinical trials helped companies quickly test whether existing medicines worked against the new virus and enabled the rapid development of COVID-19 vaccines. And work began to shore up the weaknesses evident in the healthcare supply chain. All this took place amid the broader backdrop of changes coursing through the industry and a set of long-standing common issues affecting the health ecosystem. In the years before the pandemic, and in the months since COVID-19 altered the course of history, a series of transformations has been altering traditional paradigms. And they will continue to do so in coming years. These include a heightened focus on well-being and prevention, the push to develop cures in addition to treatments, paying based on outcomes rather than fee-for-service, new developments in gene therapy and precision medicine, cross-industry convergence, and an end-to-end focus on patient and clinician experience. These themes intersect and interact with significant issues, including excessive cost; health inequities; inadequate transparency, interoperability and collaboration; and a general lack of trust.

The scope of the research study titled global hemodynamic monitoring devices market is aimed at assessing the market potential of various hemodynamic monitoring devices. The following were the types of approaches in which the global hemodynamic monitoring devices market was estimated and its growth potential for the forecast period was evaluated:

近两周沪深300 指数上涨1.92%，医药生物（申万）指数下跌2.61%，较沪深300 的相对收益为-4.53%，行业排名第24 位。分子版块来看，近两周7 个申万医药子行业涨跌分化，大部分板块有所下跌。其中SW 中药II、SW 医药商业II 实现上涨，分别上涨3.69%、0.85%，其他板块均有所下跌，其中SW 医疗器械II、SW 化药原料药跌幅较大，分别下跌3.30%、3.70%。整体来看，大部分板块表现弱于大盘。

本报告期医药生物行业指数跌幅为3.28%，在申万28 个一级行业中位居第23，跑输沪深300 指数（+0.60%）。从子行业来看，医药生物三级行业中，仅中药、生物制品上涨，涨幅分别为1.04%、0.43%；医疗服务、化学制剂、化学原料药跌幅居前，跌幅分别为8.23%、4.92%、3.30%。

2021 年10 月15 日，圆心科技提交招股书，准备赴港上市。圆心科技 是一家专注于处方药的综合医疗交付平台，2020 年，院边药店的处方 药销售贡献了97.5%的营业收入。我们对行业与公司基本面进行简单分 析，供参考。

本周新药行情回顾：2021 年10 月18 日—2021 年10 月22 日，新药 板块，涨幅前5 企业：迈博药业（+6.5%）、药明巨诺（+6.0%）、百济 神州（+5.7%）、先声药业（+5.7%）、康宁杰瑞（+5.1%）； 跌幅前5 企业：亘喜生物（-21.3%）、前沿生物（-13.6%）、康诺亚（- 7.5%）、贝达药业（-7.5%）、德琪医药（-5.2%）。

2021 年10 月21 日-26 日，微创机器人（2252.HK）招股，公司预计2021年11 月2 日开始上市交易。微创机器人是国内顶尖的手术机器人公司，公司三大核心产品：图迈®腔镜手术机器人、蜻蜓眼®三维电子腹腔内窥镜及鸿鹄®骨科手术机器人。我们对行业与公司基本面进行简单分析，仅供参考。

2021年10月22日，博腾股份发布公告拟出资成立产业基金，重点投资于高难复杂制剂领域内在关键中间体、API、制剂等环节具有生产成本优势或技术壁垒的MAH公司。公司拟认缴出资额1.225 亿元，占总额的35%，助力公司制剂事业部业务拓展，加快匹配公司原料药（API）到制剂CDMO 服务一体化的战略诉求。同时，我们发现10月11日，美国CRO Pace Analytical也收购Velesco 用于补充制剂的生产能力和规模。我们发现全球制剂CDMO布局正在明显加速。Catalent 2020年报披露，整个制剂规模市场总额超过500亿美元，预计未来五年每年增长8%以上。我们认为，随着工程师红利的逐渐弱化，中国CDMO也同样在与海外大药企的合作中，建立了一定的合作粘性，CGT、制剂CDMO等高附加值、高成长板块有望成为行业的新增长点。

本周多地区出现国庆旅行团引起的疫情散点突发情况，新冠检测需求逐步常态化，带动疫情相关股票上涨。从政策角度来看，国产替代趋势加强及医疗新基建落地，医疗设备有望加速成长；中药配方颗粒于11 月1日试点结束，各省陆续纳入医保带动中药配方颗粒销售上量，建议关注高端医疗设备和中药配方颗粒。

国内散发本土疫情，海外疫情出现反扑。10 月17 日以来，国内出现 多点散发本土疫情，呈快速发展态势，一周之内已波及内蒙古、甘肃、 宁夏、北京、河北等11 个省份。截至10 月23 日，累计报告133 例感 染者。海外疫情亦出现反扑。俄罗斯单日新增病例和死亡病例均连创 新高，10 月23 日新增超3.5 万例确诊病例，新增1072 例死亡病例。 英国近7 天新增新冠确诊病例数创7 月下旬以来单周新增确诊病例最 高纪录。截至23 日，已连续11 天新增确诊超4 万例。